Meeting
2019 Gastrointestinal Cancers Symposium
M1a disease should be reconsidered in esophageal cancer staging system from the perspective of treatment response and survival after definitive concurrent chemoradiotherapy.
Authors
Tae Ryong Chung
Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
Tae Ryong Chung , Jie-Hyun Kim , Ik Jae Lee , Yona Cho , Da Hyun Jung , Jae Jun Park , Young Hoon Youn , Hyojin Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 13)
DOI
10.1200/JCO.2019.37.4_suppl.13
Abstract #
13
Poster Bd #
E3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The implication of failure patterns after neoadjuvant chemoradiotherapy with small involved-field in esophageal squamous cell carcinoma.
First Author: Hyunju Shin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).
First Author: Changying Guo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Recurrence-free survival as a surrogate for overall survival in esophageal squamous cell carcinoma: Nationwide real-world data from Japan.
First Author: Jun Okui
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).
First Author: Changying Guo